Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death

Abstract Background Acute myeloid leukemia (AML) is a heterogeneous disease that frequently relapses after standard chemotherapy. Therefore, there is a need for the development of novel chemotherapeutic agents that could treat AML effectively. Radotinib, an oral BCR-ABL tyrosine kinase inhibitor, wa...

Full description

Bibliographic Details
Main Authors: Sook-Kyoung Heo, Eui-Kyu Noh, Ho-Min Yu, Do Kyoung Kim, Hye Jin Seo, Yoo Jin Lee, Jaekyung Cheon, Su Jin Koh, Young Joo Min, Yunsuk Choi, Jae-Cheol Jo
Format: Article
Language:English
Published: BMC 2020-12-01
Series:BMC Cancer
Subjects:
Radotinib
Acute myeloid leukemia
Cytarabine
Ara-C
Anti-leukemic activity
Online Access:https://doi.org/10.1186/s12885-020-07701-8

Internet

https://doi.org/10.1186/s12885-020-07701-8

Similar Items